ClinicalTrials.gg
Not yet recruitingNCT07535567NimoBenSeqUpdated Apr 30, 2026

Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma

A Phase 2/3 interventional study of Nimotuzumab and Nimotuzumab, Benmelstobart in Head and Neck Squamous Cell Carcinoma, sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
386
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck — 6 open to participants now, 6 under way, 2 of them phase 3. nimotuzumab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
2nd of 12
386 · median 93
Started
2026
with 3 others
Phase 2/3
Only one
of the 12
Registered
11th of 12
by date
Lead sponsor
1 of 12
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Among the 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2026, is the only one in phase 2/3, and was the 11th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

6 of the 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About nimotuzumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

A multicenter, randomized, controlled, open-label, Phase II/III clinical trial designed to evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab,with or without Bemcentinib, in postoperative head and neck squamouscell cancer patients with intermediate-risk pathological factor. The primary endpoint is the 3-year disease-freesurvival (DFS). A total of 193 patients will be enrolled in both the experimental and control groups, resulting in a total planned enrollment of 386 patients.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • intermediate-risk pathological risk factor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • performance status: 0-2
  • confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, larynx); oropharyngeal cancer must be p16-negative (p16 positivity defined as ≥70% staining)
  • Completionof curative-intent surgery, with any of the following intermediate-risk factors present postoperatively:

    ①pT3-4a;

    ②N2 disease (excluding cases with extranodal extension);

    ③Closemargin \< 5 mm;

    ④Lymphovascular and/or perineural invasion;

    ⑤Invasion depth > 5mm for T2 oral cavity cancer

  • Laboratory tests must meet the following criteria:

    ①Hematologic parameters (within 14 days without transfusion or blood products): a. (Hb) ≥80 g/L; b. (ANC) ≥ 1.0 × 10⁹/L; c. count (PLT) ≥ 80 × 10⁹/L;

    ②Biochemical parameters: a. (BIL) \< 1.5 × upperlimit of normal (); b. (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN;

  • Expected survival time ≥ 6 months;
  • Women of child bearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and agree to use reliable during the study period; Male subjects must use reliable contraception from before treatment initiation until 120 days after the last dose of study drug
  • With immunohistochemistry testing
  • Participant voluntarily agrees to participate in this study and signs the form

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation, or intention to become pregnant during the study period.
  • Presence of active disease or immunodeficiency, including but not limited to: myasthenia gravis, interstitial pneumonia, enteritis, autoimmune hepatitis, hypophysitis, vasculitis, nephritis, or hyperthyroidism.
  • Known (HIV) infection, history of autoimmune diseases, or history of organ transplantation.
  • Use of systemic drugs within 2 weeks prior to initiation of study treatment, or anticipated need for systemic immunosuppressive therapy during the study treatment period.
  • Diagnosis of another within 3 years prior to enrollment.
  • History of Grade I or higher myocardial ischemia or myocardial infarction, severe arrhythmia, or ≥ Grade 2 congestive heart failure ( [NYHA] classification) within 6 months prior to enrollment.
  • Participation in another clinical trial or completion of another clinical trial within 4 weeks prior to enrollment.
  • Prior treatment of immunotherapy (including /PD-L1/CTLA-4 antibodies) or anti-EGFR agents.
  • Known or suspected allergy to the product or any drug related to this trial.
  • Any other severe medical condition that, in the investigator's judgment, may compromise patient safety or interfere with the subject's ability to complete the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
386 participants (estimated)

Study arms

  • Experimental
    IMRT-Nimotuzumab + Benmelstobart

    Concurrent Nimotuzumab with intensity-modulated radiotherapy (IMRT), followed by adjuvant Benmelstobart therapy

    Drug: Nimotuzumab, Benmelstobart · Radiation: Postoperative Radiotherapy

  • Active comparator
    IMRT-Nimotuzumab

    Concurrent Nimotuzumab with intensity-modulated radiotherapy (IMRT)

    Drug: Nimotuzumab · Radiation: Postoperative Radiotherapy

Interventions

  • Nimotuzumab: 200 mg on Day 1, once weekly (QW) for a total of 6 cycles.

  • DrugNimotuzumab, Benmelstobart

    Drug pages: NimotuzumabStudies of NimotuzumabNimotuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BenmelstobartStudies of BenmelstobartBenmelstobart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nimotuzumab: 200 mg on Day 1, once weekly (QW) for a total of 6 cycles. Bemcentinib: 1200 mg on Day 1, every 3 weeks (Q3W) for a total of 9 cycles, initiated 3-4 weeks after completion of radiotherapy.

  • RadiationPostoperative Radiotherapy

    Intensity-modulated radiation therapy (IMRT) will be administered at a total dose of 60Gy (2 Gy per fraction, 30 fractions)

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS)

    From randomization until disease recurrence, metastasis, second primary cancer, or death from any cause

    Time frame: 3-year

Secondary outcomes

  1. Overall Survival (OS)

    From enrollment until death from any cause

    Time frame: 3-year

  2. Adverse Events (AEs)

    From the first dose of nimotuzumab through 30 days after the last dose (approximately 8 weeks total).

    Time frame: 30 days after the last dose (approximately 8 weeks total).

  3. Locoregional Recurrence-Free Survival (LRRFS)

    Time frame: From enrollment until first locoregional recurrence, assessed up to 3 years after last patient enrolled

  4. Distant Metastasis-Free Survival (DMFS)

    Time frame: From enrollment until first distant metastasis, assessed up to 3 years after last patient enrolled

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Dec 2028, 31 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 17, 2026
StartEst.
May 5, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07535567
Responsible party
Guopei Zhu (Principal Investigator, Clinical Professor, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University) — Principal investigator
First posted
Apr 17, 2026
Start date
May 5, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 30, 2026

Study contacts

Guopei Zhu
Contact
antica@gmail.com
86-23271699 ext. 5665
Wen Jiang
Contact
wjiang91@163.com
86-23271699 ext. 5665

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nimotuzumab · Benmelstobart

Start the discussion